1.Clinical significance of platelet count, C-Reaction protein and D-Dimer in kawasaki disease children with coronary artery lesion
Xiaobin WENG ; Jinfang BAO ; Qingsong ZHENG
Chinese Journal of Biochemical Pharmaceutics 2017;37(8):432-433,436
Objective To explore the clinical significance of platelet count, C-reaction protein and D-dimer in Kawasaki disease children with coronary artery lesion. Methods 54 cases of children with KD treated in our hospital from January 2013 to December 2015 were divided into coronary artery injury (CAL) group (n=15) and without coronary artery injury (NCAL) group (n=39), according to the cardiac ultrasound examination. The relationship between the changes of platelet count, C reactive protein and D- two and coronary artery lesion in the 2 groups of acute and convalescent stages were detected. Platelet count, C-reaction protein and D-dimer of 54 healthy children were measured as a control. Results The levels of the platelet count, C-reaction protein and D-dimer of the KD children during acute stage are significantly higher than the control group (P<0.05), while the levels of C-reaction protein and D-dimer of the KD children during recovery stage was significantly decreased after treatment (P<0.05), the platelet count is remarkably increased (P<0.01). The platelet count, C-reaction protein and D-dimer for the KD children with coronary artery malformation, either at acute stage or recovery stage, compared with the control group were significantly different (P<0.05), with statistical significance. Conclusion The changes of the platelet count, C-reaction protein and D-dimer levels have close relations with the cardiovascular damage to the KD children.
2.Clinical study of milrinone in the treatment of children with congenital heart disease complicated by severe pneumonia and heart failu
Jinfang BAO ; Xiaobin WENG ; Jianwei JI
Chinese Journal of Biochemical Pharmaceutics 2017;37(8):183-184,188
Objective To investigate the clinical effect of milrinone in the treatment of children with congenital heart disease complicated by severe pneumonia and heart failure. Methods 94 patients with congenital heart disease complicated with severe pneumonia and heart failure in our hospital from March 2014 to February 2016 were selected,and randomly divided into experimental group and routine group,47 cases in each groups. The routine group were treated with conventional treatment, the experimental group in the conventional group received routine treatment based on the same given milrinone treatment. The clinical efficacy, symptom disappearance time and adverse reactions were compared between the two groups. Results The treatment in the experimental group the total efficiency (93.62%) was significantly higher than that of the conventional treatment group with the total effective rate (78.72%), significant difference, statistically significant (P<0.05); the experimental group in children with fever, cough, rales and other symptoms disappeared time is lower than the conventional group, the data had significant difference, has statistical significance (P<0.05); two groups of patients during treatment were not any serious adverse reactions, the adverse reaction condition no difference does not have statistical significance.Conclusion The clinical effect of milrinone in the treatment of children with congenital heart disease complicated by severe pneumonia and heart failure significantly, clinical efficacy, low incidence of adverse reactions, worthy of promotion.
3.Influencing factors of erythropoietin hyporesponsiveness in patients on maintenance peritoneal dialysis and their prognostic value
Jun LIU ; Jing HAO ; Li ZHANG ; Jinfang BAO ; Qing YU ; Weijie YUAN
Chinese Journal of Nephrology 2008;24(5):304-308
Objective To investigate the factors associated with hyporesponsiveness to erythropoietin (EPO) in patients on maintenance peritoneal dialysis (PD) . Methods Data of 114 PD patients in our PD center were collected . Patients were divided into three groups according to weekly EPO dose: hyperresponsive, hyporesponsive and normal responsive . Various factors were compared among three groups by linear correlation and ordinal regression analysis to predict EPO resistance . Results As compared to hyperresponsive and normal responsive groups,significantly lower serum hemoglobin [(78 .11±13 .42) vs (106 .28±23 .83), (96 .31±12 .33) g/L],albumin [(33 .98±4 .78) vs (39 .72±4 .26), (35 .76±4 .88) g/L], and significantly higher serum CRP [(26 .08±21 .66) vs (5 .46±1 .75), (11 .82±5 .63) mg/L], ferritin [(371 .08±89 .38) vs (289 .39±76 .84),(323 .07±62 .46) μg/L] were found in hyporesponsive group(all P < 0 .01) . Erythropoietin resistance index (ERI) was correlated with CRP and albumin . Regression analysis showed that serum albumin,CRP and ferritin were strong predictors of EPO hyporespnsiveness . Conclusions Serum albumin,CRP and ferritin are closely related to hyporesponsiveness . Malnutrition and inflammatory state contribute to EPO hyporesponsiveness .
4.Expression of Rabies Virus Glycoprotein Gene in Saccharomyces cerevisiae
Hui ZHAO ; Wenling ZHENG ; Yang GAO ; Jinfang ZHANG ; Yifei PENG ; Bao ZHANG ; Wenli MA
Microbiology 2008;0(11):-
To obtain non-pathogenic rabies virus glycoprotein(RV-G),we expressed RV-G in Saccaromyces Cerevisiae(S.cerevisiae).In our study,tat-G fusion gene was cloned into the expression vector pYes2.0,which allows expression of a foreign gene in the yeast cells under the control of GAl1 promoter.Transforma-tion was performed by using lithium-treated yeast cells and several Ura+-tranformants were isolated.Ac-cording to the relative mobility in SDS-PAGE,we know probably two forms(designated as yGI and yGⅡ) of RV-G analogues produced in S.cerevisiae,their molecular weights were estimated as 66 kD and 56 kD,respectively.On the other hand,there was a specific band about 56 kD shown in western blot result.Com-bining precursors’ achievements,we will draw a conclusion that trans-membrane domain(TD) and cyto-plasmic domain have a negative regulation on RV-G antigen immunogenicity in S.cerevisiae.
5.Effect of intermittent suction of budesonide on lung function and recurrence in infants with wheezing
Xiaobin WENG ; Jinfang BAO ; Qingsong ZHENG ; Zhenjie CHEN
Chinese Journal of Primary Medicine and Pharmacy 2018;25(4):495-498
Objective To observe the effect of intermittent inhalation of budesonide on lung function and recurrence in asthmatic infants .Methods 120 children with recurrent wheezing and asthma predictive index were selected.They were randomly divided into control group and observation group according to the digital table ,60 cases in each group .The two groups were given conventional treatment .The observation group was treated with high dose of inhaled budesonide in the acute phase for 7 days,and stopped after the symptoms were controlled .However,cold air or acute infection caused wheezing recurrence ,used the above dose for 7 days to control the wheezing symptoms ,if not properly controlled to extend the treatment time so that wheezing control .In the control group ,children were treated with foggy cans inhalation of fluticasone propionate aerosol .After the symptoms were controlled ,the dose was reduced for 3 months.If the cold air or the occurrence of acute wheezing ,should be treated in time.The time of disappearance of wheeze in the lungs of the two groups was observed .The changes of lung function were observed before and after treatment for 6 months.The number of recurrent respiratory tract infections was observed in the two groups during this period.Results The disappearance time of wheeze ,cough,wheezing rale between the two groups had no statistically significant differences(t =0.67,P =0.25;t =0.96,P =0.17;t =1.60,P =0.06).Before treatment,the lung function indicators between the two groups had no statistically significant differences (all P>0.05).After treatment, TV,VPFE/VE,TPTEF/TE of the two groups were improved (all P<0.05),and there were no statistically significant differences between the two groups (all P>0.05).The number of respiratory infections ,the number of wheezing and the duration of wheezing in the observation group were less than those in the control group (t=14.72,P=0.00;t=9.15,P=0.00;t=6.97,P=0.00).There were 5 cases of hoarseness and 4 cases of rash in the control group .There were no serious adverse reactions in the observation group ,the difference was statistically significant (χ2 =9.73,P=0.002).Conclusion Intermittent inhalation of budesonide suspension can improve the clinical symptoms and improve lung function in children .It is better than long -term inhaled glucocorticoid in prevention of wheezing and with safety.It is suitable for clinical use .
6.Clinical features and outcomes in acute ischemic stroke patients with remote symptomatic intracranial hemorrhage after intravenous thrombolysis
Jinfang ZHOU ; Wanhua WANG ; Zhaoxi MA ; Yan ZHANG ; Jieming REN ; Hongzhou WANG ; Liyun LU ; Zhicheng BAO ; Yongjun CAO ; Qi FANG
International Journal of Cerebrovascular Diseases 2017;25(5):412-415
ObjectiveTo investigate clinical features and outcomes in acute ischemic stroke patients with remote symptomatic intracranial hemorrhage (sICHr) after intravenous thrombolysis.MethodsThe acute ischemic stroke patients with sICHr after intravenous thrombolysis therapy were enrolled retrospectively.The clinical data were collected and the related literature was analyzed and summarized.ResultsA total of 6 acute ischemic stroke patients with sICHr were enrolled, including 4 males.Three patients had a history of using antiplatelet agents, 2 with atrial fibrillation, 4 with hypertension, 3 with previous stroke history, 4 with smoking history, and 4 had sICHr at 2 h after intravenous thrombolysis.Of the 14 hemorrhagic foci (except in the infarct areas), 10 were in the cerebral cortex.Three patients died within 1 week, and 1 was in a persistent vegetative state.Conclusions SICHr after intravenous thrombolysis in patients with acute ischemic stroke is mainly located in the cerebral cortex.The outcomes in acute ischemic stroke patients with SICHr after intravenous thrombolysis are poor, and the mortality is high.
7.Multidrug resistance of enteric bacilli and its relation to structure and molecular evolution of variable region in resistance-related class-I integron.
Huan WANG ; Qiyu BAO ; Aihua SUN ; Jinfang ZHAO ; Yumei GE ; Jie YAN
Journal of Zhejiang University. Medical sciences 2013;42(2):149-155
OBJECTIVETo investigate the drug resistance of enteric bacilli and its relation to the drug resistance gene cassette in the variable region and molecular evolution of class-I integron.
METHODSK-B assay was applied to measure the drug resistance of E.coli, E.cloacae and A.baumannii isolated against twelve antibiotics. The class-I integron and drug resistance gene cassettes in the variable region of the integron were detected by PCR and sequencing of amplification products. The molecular evolution of drug resistance genes in the class-I integrons was analyzed using Clustal X and MEGA software.
RESULTS54.2%-100% of A.baumannii isolates were resistant to the penicillin and cephem antibiotics, while E.coli and E.cloacae isolates had resistance rates of 41.6%-62.5% to cephem antibiotics. 62.5%(15/24) of E.coli, 67.9%(19/28) of E.cloacae and 83.3%(20/24) of A.baumannii isolates were positive for class-I integrons. 81.5% (44/54) of class-I integrons showed 4 different single band spectrums and the other class-I integrons displayed 3 different double band spectrums. In the drug resistance gene cassettes in variable regions of class-I integrons there were 7 types in 4 groups of drug resistance genes, including aac(6'), sad(3"), aad(2"), cat(4') and dfr (types 7, A13 and 15), which induced the resistance to aminoglycosides and sulfamido antibiotics and chloromycin. The class-I integrons in the isolates might be divided into 4 molecular evolution groups according to the diversity of dihydrofolate reductase encoding gene sequences.
CONCLUSIONThe enteric bacilli have a high drug resistance and frequently carry class-I integrons with 7 drug resistance gene cassettes which present 4 different evolutionary pathways.
Anti-Bacterial Agents ; pharmacology ; Drug Resistance, Multiple, Bacterial ; genetics ; Enterobacteriaceae ; drug effects ; genetics ; Evolution, Molecular ; Integrons ; genetics
8.Effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance
Chuanlei LI ; Yun XIE ; Zhihuang ZHENG ; Kexin XU ; Nan ZHU ; Xiujuan ZANG ; Xuemin WANG ; Jinfang BAO ; Qing YU ; Ruilan WANG ; Jun LIU ; Zhigang ZHOU
Chinese Critical Care Medicine 2021;33(7):815-820
Objective:To investigate the clinical effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance.Methods:A prospective randomized controlled trial was conducted. From March 2019 to April 2020, septic patients with syndrome of heat-toxin exuberance admitted to intensive care unit (ICU) of Shanghai General Hospital and Songjiang Branch of Shanghai General Hospital were enrolled as the research objects, and they were divided into routine treatment group and Jiedu Limai decoction group by the random number table method. Patients in both groups were given standard treatment in accordance with the guidelines, and patients in the Jiedu Limai decoction group were given Jiedu Limai decoction in addition to the standard treatment, once a day for 14 days. The 28-day survival of patients of the two groups were recorded, the acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score, sequential organ failure assessment (SOFA) score, coagulation indexes, infection indexes, inflammatory cytokines and organ function indicators before treatment and 7 days after treatment in both groups were recorded, and the prognosis of the two groups were recorded.Results:A total of 259 patients with infection or clinical diagnosis of infection admitted during the experimental observation period were included, and those who did not meet the Sepsis-3 diagnostic criteria, more than 80 years old or less than 18 years old, with multiple tumor metastases, autoimmune system diseases, with length of ICU stay less than 24 hours, with acute active gastrointestinal bleeding and with incomplete data were excluded. One hundred patients were finally enrolled, with 50 patients in the routine treatment group and 50 patients in the Jiedu Limai decoction group. There were no statistically significant differences in coagulation indexes, infection indicators, inflammatory cytokines and organ function indicators before treatment between the two groups. After 7 days of treatment, the coagulation indexes, infection biomarkers and inflammatory cytokines in the Jiedu Limai decoction group were significantly lower than those in the routine treatment group [D-dimer (mg/L): 2.2 (1.8, 8.5) vs. 4.0 (1.5, 8.7), fibrinogen (Fib, g/L): 3.7 (3.4, 4.3) vs. 4.2 (3.7, 4.3), fibrinogen degradation product (FDP, mg/L): 7.2 (5.4, 10.2) vs. 13.2 (9.2, 15.2), procalcitonin (PCT, μg/L): 0.4 (0.2, 2.9) vs. 0.5 (0.2, 0.9), C-reactive protein (CRP, mg/L): 50.1 (9.5, 116.0) vs. 75.1 (23.5, 115.2), interleukin-6 (IL-6, ng/L): 31.6 (21.6, 81.0) vs. 44.1 (14.0, 71.3), all P < 0.05], and the levels of B-type brain natriuretic peptide (BNP) and kidney injury molecule-1 (KIM-1) were significantly lowered [BNP (ng/L): 261.1 (87.5, 360.3) vs. 347.3 (128.8, 439.4), KIM-1 (μg/L): 0.86 (0.01, 1.40) vs. 1.24 (1.05, 1.57), both P < 0.05]. Compared with the routine treatment group, the number of new organ failure in the Jiedu Limai decoction group was decreased (30.0% vs. 50.0%, P < 0.05). Although there was no significant difference in 28-day mortality between the two groups ( P > 0.05), the 28-day mortality in the Jiedu Limai decoction group was lower than that in the routine treatment group (18.0% vs. 24.0%). Conclusion:Combining Jiedu Limai decoction to the sepsis guideline in treating syndrome of heat-toxin exuberance can effectively improve patients' coagulation function, the situation of heart and renal injury, reduce the level of inflammatory cytokines, and fewer people develop new organ failure after treatment.
9.Establishment of a RT-PCR assay for detection of mRNA expression of KIR2DS1 gene on NK cell surface
Tian WANG ; Ying LI ; Xing HU ; Huanhuan ZHANG ; Luyao CHEN ; Xiaojing BAO ; Jinfang SHI ; Jun HE
Chinese Journal of Clinical Laboratory Science 2019;37(11):825-830
Objective:
To establish a real-time PCR (RT-PCR) assay for detecting mRNA expression of killer cell immunoglobulin-like receptor (KIR) 2DS1 gene( KIR2DS1 ) on the surface of natural killer (NK) cells, and evaluate its performance.
Methods:
A total of 57 recipient-donor pairs of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) were enrolled in this study. The specific primers and probe of KIR2DS1 gene were designed for Taqman-MGB fluorescence quantitative PCR detection system. The performance parameters of the detecting system, such as coincidence rate, repeatability, sensitivity, scope of application of the instrument and reproducibility of operation technicians were evaluated and validated.
Results:
The KIR-SSO Genotyping Test was used as the gold standard. The results of 35 samples showed the accuracies of self-built method were all 100% for both of positive and negative KIR2DS1 . Three samples with high, median and low value of Ct values were used to verify the repeatability. The coefficients of variation of intra-assay and inter-assay were ranged from 0.09% to 0.46% and 0.71% to 1.13% respectively. The sensitivity of the established method was up to 10 2 copies/μL at least. The coefficients of variation of the three samples with sensitivity of 10 2 copies/μL were 5.37%, 2.71% and 5.51% in five repeated tests respectively. The regression analysis for the samples measured by ABI-7500 and LC-480 fluorescence quantitative PCR instrument showed regression equation was Y=0.973 6X+0.118 3 (R 2 =0.961 9, R 2 >0.95). The reproducibility of 10 samples with positive KIR2DS1 operated by two technicians showed that the biases were all less than ±5%.
Conclusion
A TaqMan-MGB real-time PCR assay for detection of mRNA expression of KIR2DS1 gene was established successfully with fine performance.
10.Chinese expert consensus on clinical treatment of adult patients with severe traumatic brain injury complicated by corona virus disease 2019 (version 2023)
Zeli ZHANG ; Shoujia SUN ; Yijun BAO ; Li BIE ; Yunxing CAO ; Yangong CHAO ; Juxiang CHEN ; Wenhua FANG ; Guang FENG ; Lei FENG ; Junfeng FENG ; Liang GAO ; Bingsha HAN ; Ping HAN ; Chenggong HU ; Jin HU ; Rong HU ; Wei HE ; Lijun HOU ; Xianjian HUANG ; Jiyao JIANG ; Rongcai JIANG ; Lihong LI ; Xiaopeng LI ; Jinfang LIU ; Jie LIU ; Shengqing LYU ; Binghui QIU ; Xizhou SUN ; Xiaochuan SUN ; Hengli TIAN ; Ye TIAN ; Ke WANG ; Ning WANG ; Xinjun WANG ; Donghai WANG ; Yuhai WANG ; Jianjun WANG ; Xingong WANG ; Junji WEI ; Feng XU ; Min XU ; Can YAN ; Wei YAN ; Xiaofeng YANG ; Chaohua YANG ; Rui ZHANG ; Yongming ZHANG ; Di ZHAO ; Jianxin ZHU ; Guoyi GAO ; Qibing HUANG
Chinese Journal of Trauma 2023;39(3):193-203
The condition of patients with severe traumatic brain injury (sTBI) complicated by corona virus 2019 disease (COVID-19) is complex. sTBI can significantly increase the probability of COVID-19 developing into severe or critical stage, while COVID-19 can also increase the surgical risk of sTBI and the severity of postoperative lung lesions. There are many contradictions in the treatment process, which brings difficulties to the clinical treatment of such patients. Up to now, there are few clinical studies and therapeutic norms relevant to sTBI complicated by COVID-19. In order to standardize the clinical treatment of such patients, Critical Care Medicine Branch of China International Exchange and Promotive Association for Medical and Healthcare and Editorial Board of Chinese Journal of Trauma organized relevant experts to formulate the Chinese expert consensus on clinical treatment of adult patients with severe traumatic brain injury complicated by corona virus infection 2019 ( version 2023) based on the joint prevention and control mechanism scheme of the State Council and domestic and foreign literatures on sTBI and COVID-19 in the past 3 years of the international epidemic. Fifteen recommendations focused on emergency treatment, emergency surgery and comprehensive management were put forward to provide a guidance for the diagnosis and treatment of sTBI complicated by COVID-19.